(Date:1/8/2009)...nce of relief organizations offers five action ste...PRNewswire-USNewswire/ -- Despite the recent three...d medical supplies to residents of the Palestinian...ccess to food, clean water and medical help. U.S.-... working in the region see this arrangement to all...
(Date:1/8/2009)...ude study could shape new treatments for secondary...re-USNewswire/ -- Scientists at St. Jude Children,...tive treatment for bacterial pneumonia following i...cin and azithromycin, which kill bacteria by inhib...than a standard first-line treatment with the "bet...
(Date:1/8/2009)...l dance students will dance to raise money for Cam...an. 8 , , , WHO: Dan...off their talent in the 3rd annual Dance, ...Arts Centre. The, event will be e... Participants raise money through pl...
(Date:1/8/2009)...., Jan. 8 /PRNewswire-Asia/ -- Chindex Internation...y"), a leading independent American,provider of W...ple,s Republic,of China, today announced that the...onference, to be held in Shanghai on January 12th ...erence will be held at the Pudong Shangri-,La hot...
Breaking Medicine News(10 mins):Health News:Temporary Cease Fires Not Enough for Humanitarian Aid Groups Working in Gaza 2Health News:Temporary Cease Fires Not Enough for Humanitarian Aid Groups Working in Gaza 3Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:Dance With Courage to Benefit Camp Courage 2Health News:Chindex International Inc. Announces Participation in the 2009 UBS Greater China Conference 2...onounsaturated fats and carbohydrates can be inclu...ering more variety. Research done by Dr. Anurag Ga...own the benefits// of mono-unsaturated fats on hea...abetes place an emphasis on fats like olive, canol...
...he heart-shocking devices known as defibrillators ...den death in nearly one-third of the patients. //D...atic and costly shift in the way they treat millio... a $20,000 defibrillator to the medicines now in u...
...ng heart arteries flowing smoothly after angioplas...ors released the longest follow-up with the new te...0 patients over 3 years, they found it to be 100 p...n Americans undergo angioplasty annually, and the ...
...ilure victims who get a new kind of pacemaker have...th worsening heart trouble.// The device, Medtroni...han 3,000 people in the US since its approval by t...th a particular form of heart failure, a debilitat...
Other Medicine News:(Date:1/6/2009)...ire/ -- Sequella, Inc., a clinical-stage biopharma...otential, announced today that SQ109, its lead dru..., was the first drug approved for evaluation in a ... Vaccine Company LLC and Quintiles Transnational. ... Allergy and Infectious Diseases (NIAID), National...
(Date:1/6/2009)...-- Pacira Pharmaceuticals, Inc., an,acute care sp...at enrollment,has been completed in two pivotal P... efficacy of a single intraoperative administratio...postoperative analgesia. , Results from the...throplasty (TKA) are expected to provide the prima...
(Date:1/5/2009)...harmaceuticals announced today that it has initiat...n kinase inhibitor, CX-4945, in patients with adva...e myeloma. The primary endpoints of the oral dose ...rance and PK properties of CX-4945 and to select t...on, multiple mechanism-related pharmacodynamic bio...
(Date:1/5/2009)...-- Women undergoing in vitro,fertilization (IVF) ...rly,pregnancy, but the intramuscular injections f...or patients. Formulations of progesterone medicat...ection or vaginal suppository may offer,similar r...h patient well-being a constant focus, Fertility P...
Breaking Medicine Technology:Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF 2Wait Educate Before You Self Medicate 14792 1Wait Educate Before You Self Medicate 14792 2Wait Educate Before You Self Medicate 14792 3Wait Educate Before You Self Medicate 14792 4Nereus Pharmaceuticals Initiates Clinical Trial of NPI 2358 in Non Small Cell Lung Cancer Following Encouraging Phase 1 Data 4104 1Nereus Pharmaceuticals Initiates Clinical Trial of NPI 2358 in Non Small Cell Lung Cancer Following Encouraging Phase 1 Data 4104 2Nereus Pharmaceuticals Initiates Clinical Trial of NPI 2358 in Non Small Cell Lung Cancer Following Encouraging Phase 1 Data 4104 3AstraZenecas Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non Small Cell Lung Cancer by 2016 4102 1AstraZenecas Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non Small Cell Lung Cancer by 2016 4102 2Electrophysiology Procedures for Atrial Fibrillation Treatment to Grow Over 25 25 Annually Over the Next Five Years 4100 1Electrophysiology Procedures for Atrial Fibrillation Treatment to Grow Over 25 25 Annually Over the Next Five Years 4100 2..., Independent Japanese study demonstrates dramatic... , , , Study halted early due to superior outcomes...April 27, 2007 - New findings from the independen...[1], show that,adding the blood pressure lowering ...duced a dramatic 39% reduction in,cardiovascular e...
...RVINE, Calif.--(BUSINESS WIRE)--Apr 30, 2007 - Cob...pment company specializing in,anti-allergy medicat...independent contract research organization that it...cked data bases into a single,database before un-b...quired to generate top-line results for Cobalis, t...
Other Medicine Technology:Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7Cobalis Expects to Report Phase III Top-Line Results in May 2